期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

siRNA-Smad3对乳腺癌MCF-7细胞株CyclinE表达影响的研究 被引量：4

下载PDF
导出
摘要 RNA干扰（RNAinterference，RNAi）是最近几年发展起来的一种抑制基因表达的有效方法，它是通过外源双链RNA（double—strandedRNA，dsRNA）的介导特意地降解相应序列的mRNA，阻断相应基因表达，属于转录后基因沉默（post--transcriptiongenesilencing，PTGS）的一种形式。
作者 秦优优 杨学伟 崔武 马飞虹
机构地区 哈尔滨医科大学第二附属医院普外八科 黑龙江省卫生厅 佳木斯大学附属第一医院介入放射科
出处 《黑龙江医药科学》 2011年第4期67-68,共2页 Heilongjiang Medicine and Pharmacy
关键词 SIRNA TGF-Β SMAD3 CYCLINE 乳腺癌
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献19

  • 1Samuels V, Barrett JM, Bockman S, et al. Immunocytochemical study of transforming growth factor expression m begin and malignant gliomas. Am J Pathol, 1989, 134 : 895-902.
  • 2Kjellman C, Olofssn SP, Hansson O, et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer, 2000, 89:251-258.
  • 3Piek E, Westermark U, Kastemar M, et al. Expression of transfoming-growth-factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-betal. Cancer, 1999, 80:756-763.
  • 4Kleeff J, Ishiwata T, Maruyama H, et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancern. Oncogene,1999, 18: 5363-5372.
  • 5Atsuzaki K, Date M, Furukawa F, et al. Regulatory mechanisms for transforming growth factor beta as an autocrine inhibitor in hunman hepatocellular carcinoma: implication for roles of smads in its growth. Hepatology, 2000, 32: 218-227.
  • 6Cui W, Fowlis DJ, Bryson S, et al. TGF-β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenie mice. Cell, 1996, 86:531-542.
  • 7Yang X, Letterio J J, Chen L, et al. Targeted disruption of Smad3 results in imparired mucosalimmunity and diminished T cell responsiveness to TGF-beta. EMBO J, 1999, 18:1280-1291.
  • 8Yamada N, Kato M, Yamashita H, et al. Enhanced expression of transforming growth factor-beta and its type- Ⅰ and type- Ⅱ receptors in human glioblastoma. Int J Cancer, 1995, 62 : 386-392.
  • 9Wang, T. C., R. D. Cardiff, L. Zukerberg, E. Lees,A. Arnold & E. V. Sehmidt, 1994, Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature, 369(6482): 669-671.
  • 10Ormandy, C. J., E. A. Musgrove, R. Hui, R. J. Daly & R. L. Sutherland, 2003, Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat, 78(3): 323-335.

共引文献19

同被引文献42

  • 1白杨,魏秀梅,叶龙,李晓京,毕继鑫,丁帅芳,路阳,钟秀宏.P27、CyclinE在卵巢癌中的研究进展[J].吉林医药学院学报,2013,34(2):146-148. 被引量：3
  • 2董磊,宋张娟.宫颈鳞癌中p16、p21^(WAF1)、Rb、cyclinE蛋白的表达[J].临床与实验病理学杂志,2004,20(5):554-556. 被引量：15
  • 3Mizoguchi M, Kuga D, Guan Y, et al. Loss of hete- rozygosity analysis in malignant gliomas [J]. Brain Tumor Pathol, 2011, 28 (3): 191-196.
  • 4Wen PY, Kesari S. Malignant gliomas in adults [J]. N Engl J Med, 2008, 359 (5): 492-507.
  • 5Piccolo SR, Frew LJ. Clinical and molecular models of glioblastoma multiforme survival [J]. Inr J Data Min Bioinform, 2013, 7 (3): 245-265.
  • 6Omar Flores, Kerry L. Burnstein, nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition[J]. Endocrinology, 2010, 151 (3): 896-908.
  • 7Xue JD, Anding L, Zhuan Z, et al. siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells [J]. BMC Cancer 2009, 9: 133.
  • 8Quon K, Kassner PD. RNA interference screening for the discovery of oncology targets.Expert Opin Ther Targets[J]. 2009, 13 (9): 1027-1035.
  • 9Hidaka T, Hama S, Shrestha P, et al. Combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high grades strocytoma[J]. Anticancer Res, 2009, 29 (2): 597-603.
  • 10Nanos-Webb A, Jabbour NA, Muhani AS, et al. Tar- geting low molecular weight cyclin E (LMW-E)in breast cancer [J]. Breast Cancer Res Treat, 2012, 132 (2): 575-588.

引证文献4

二级引证文献5

黑龙江医药科学
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部